Sprint Bioscience AB (OSTO:SPRINT) FCF Margin % : -56.20% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sprint Bioscience AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sprint Bioscience AB's Free Cash Flow for the three months ended in Mar. 2024 was kr-10.04 Mil. Sprint Bioscience AB's Revenue for the three months ended in Mar. 2024 was kr17.87 Mil. Therefore, Sprint Bioscience AB's FCF Margin % for the quarter that ended in Mar. 2024 was -56.20%.

As of today, Sprint Bioscience AB's current FCF Yield % is 16.54%.

The historical rank and industry rank for Sprint Bioscience AB's FCF Margin % or its related term are showing as below:

OSTO:SPRINT' s FCF Margin % Range Over the Past 10 Years
Min: -190.84 Med: -102.87 Max: 40.44
Current: 22.06

During the past 13 years, the highest FCF Margin % of Sprint Bioscience AB was 40.44%. The lowest was -190.84%. And the median was -102.87%.

OSTO:SPRINT's FCF Margin % is ranked better than
93.11% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs OSTO:SPRINT: 22.06

Sprint Bioscience AB FCF Margin % Historical Data

The historical data trend for Sprint Bioscience AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sprint Bioscience AB FCF Margin % Chart

Sprint Bioscience AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-83.77

-190.84

-121.96

40.44

Sprint Bioscience AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-28,692.68	100.01	-24.67	-56.20

Competitive Comparison of Sprint Bioscience AB's FCF Margin %

For the Biotechnology subindustry, Sprint Bioscience AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sprint Bioscience AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's FCF Margin % falls into.

Sprint Bioscience AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Sprint Bioscience AB's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	20.417	/	50.485
	=	40.44 %

Sprint Bioscience AB's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-10.043	/	17.871
	=	-56.20 %

Sprint Bioscience AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Sprint Bioscience AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sprint Bioscience AB (OSTO:SPRINT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sprint Bioscience AB (OSTO:SPRINT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

5JA1:Germany

Address

Halsovagen 7, Floor 8, Elevator A, Novum, Huddinge, SWE, 141 57

Website

http://www.sprintbioscience.com

Sprint Bioscience AB is a Sweden based company involved in developing drugs focused on cancer and metabolism. The project portfolio of the company includes STK25, VPS34, and PIP4K2.

Sprint Bioscience AB (OSTO:SPRINT) Headlines

No Headlines